Pimagedine

Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug.[1] Pimagedine is a diamine oxidase and nitric oxide synthase inhibitor. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone.

Pimagedine
Skeletal formula of a pimagedine
Spacefill model of a pimagedine
Names
IUPAC name
2-Aminoguanidine
Other names
  • Aminoguanidine
  • Guanyl hydrazine
  • Hydrazinecarboximidamide
  • Imino semicarbazide
  • Monoaminoguanidine
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.001.076
KEGG
PubChem CID
UNII
Properties
Chemical formula
 CH6N4
Molar mass 74.085 g/mol
Density 1.72 g/ml
Boiling point 261 °C (502 °F; 534 K)
log P −1.475
Related compounds
Related compounds
 Guanidine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Development as a potential drug

Pimagedine was under development as a drug for kidney diseases by the pharmaceutical company Alteon (now known Synvista Therapeutics Inc.) that was founded in 1986.[2]

In 1987, Alteon acquired a license to intellectual property relating to AGE inhibition from Rockefeller University.[3]

In 1989, Alteon and Marion Merrell Dow Inc (MMD) entered into a joint development program for pimagedine.[4]

In 1992, Alteon licensed a patent from Rockefeller University relating to the use of pimagedine to inhibit AGE formation.[3]

In 1995, Hoechst AG (now sanofi-aventis) acquired MMD and subsequently terminated its agreement with Alteon, which led Alteon to stop of all clinical trials due to lack of funds, which caused some controversy.[4]

In 1997, Alteon and Genentech announced a collaboration agreement under which Genentech would fund development of pimagedine and would have the rights to sell the drug if it would be approved.[5]

In March 1998, Alteon announced that it had been advised that it should discontinue its Phase III trial of pimagedine in non-insulin-dependent (type II) diabetes patients with overt nephropathy, after the trial's external safety monitoring committee found an increased risk of side effects in the treatment group.[6]

In November 1998, Alteon announced that its Phase III trial for pimagedine as a treatment for end stage renal disease had failed to prove efficacy, which led Carl Gordon, a leading biotech analyst, to say: "It looks like pimagedine is probably finished."[7]

In February, 1999, Genentech ended its collaboration with Alteon to develop pimagedine.[8]

In April 1999 Alteon announced that it would cease development of pimagedine as a treatment for end stage renal disease but might consider continuing development in type 1 diabetic patients with overt nephropathy or progressive kidney disease.[9]

Alteon's 2000, 2001, 2002 annual reports indicated that it was not running any clinical trials on pimagedine but was seeking co-development partners.[10][11][12] Alteon's 2003 and subsequent annual reports did not mention that Alteon was seeking partners for pimagenine,[13] which indicated that efforts to interest other companies and investors had failed and which signaled that commercial efforts to develop pimagedine as a drug were indeed finished.

References
  1. W Kline Bolton, Emaad Abdel-Rahman (2002). "Pimagedine: a novel therapy for diabetic nephropathy". Expert Opinion on Investigational Drugs. 11 (4): 565–574. doi:10.1517/13543784.11.4.565. PMID 11922864.
  2. Synvista Therapeutics Inc. Biocentury. Retrieved August 17, 2017.
  3. "Alteon 10-K For the fiscal year ended December 31, 1996". Alteon via SEC Edgar. March 27, 1997.
  4. Harry Keen; JH Fukker; G Menzinger (July 19, 1997). "Early closure of European Pimagedine trial". The Lancet. PlumX Metrics. 350 (9072): 214–215. doi:10.1016/S0140-6736(97)26029-0. PMID 9250200.
  5. Barbara Marsh (January 3, 1998). "Biotech's New Watchword: Partnership". Los Angeles Times. Retrieved August 17, 2017.
  6. "Alteon May Drop Pimagedine In NIDDM". The Pharma Letter. March 19, 1998. Retrieved August 17, 2017.
  7. "Alteon Shares Plummet On Poor Pimagedine Test Results". San Diego Source. November 16, 1998. Retrieved August 17, 2017.
  8. http://business.globe24h.com/sec/001/06/060000/0000060271.shtml
  9. "Alteon's pimagedine fails primary endpoint". The Pharma Letter. April 12, 1999. Retrieved August 17, 2017.
  10. https://www.sec.gov/Archives/edgar/data/878903/0000893220-00-000381.txt
  11. https://www.sec.gov/Archives/edgar/data/878903/000089322001000240/0000893220-01-000240.txt
  12. https://www.sec.gov/Archives/edgar/data/878903/000089322002000222/0000893220-02-000222.txt
  13. https://www.sec.gov/Archives/edgar/data/878903/000089322003000272/0000893220-03-000272.txt


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.